ARGX-113の新興薬剤に関する洞察と市場予測：2032年

エフガルチギモド（ARGX-113）は、IgGを介する自己免疫疾患に対する治験中の治療薬であり、IgG抗体とリサイクル受容体FcRnの自然な相互作用を利用するように設計されました。アルジェンクスは、循環する疾患の原因となる自己免疫抗体を分解するエフガルチギモドを設計し、多発性硬化症、免疫性血小板減少症（ITP）、全身性エリテマトーデス、重症筋無力症、皮膚水疱性疾患など、多くの大型および希少適応症における可能性を有しています。

エフガルチギモドは、アルジェンクス独自のABDEG技術によりIgG1抗体のFc部分を修飾し、FcRnに対する親和性を通常のIgG抗体よりも高めたものです。その結果、エフガルチギモドはFcRn結合による抗体のリサイクルを阻害し、自己免疫疾患の原因となるIgG自己抗体の迅速な枯渇をもたらします。エフガルチギモドの開発研究は、E. Sally Ward教授（テキサス大学サウスウェスタンメディカル校およびテキサスA&M大学ヘルスサイエンスセンター、テキサスA&M大学（TAMHSC）の一部）との緊密な共同研究により行われています。この薬剤は現在、原発性ITPの成人患者を対象とした第III相試験中です。

当レポートでは、主要7ヶ国におけるARGX-113市場について調査し、市場の概要とともに、2024年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 免疫性血小板減少症（ITP）に対するARGX-113の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 ARGX-113市場評価

• ITPに対するARGX-113の市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国におけるITPに対するARGX-113の市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: ARGX-113, Clinical Trial Description, 2023
• Table 2: ARGX-113, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: ARGX-113 Market Size in the 7MM, in USD million (2019-2032)
• Table 6: ARGX-113 Market Size in the US, in USD million (2019-2032)
• Table 7: ARGX-113 Market Size in Germany, in USD million (2019-2032)
• Table 8: ARGX-113 Market Size in France, in USD million (2019-2032)
• Table 9: ARGX-113 Market Size in Italy, in USD million (2019-2032)
• Table 10: ARGX-113 Market Size in Spain, in USD million (2019-2032)
• Table 11: ARGX-113 Market Size in the UK, in USD million (2019-2032)
• Table 12: ARGX-113 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: ARGX-113 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: ARGX-113 Market Size in the United States, USD million (2019-2032)
• Figure 3: ARGX-113 Market Size in Germany, USD million (2019-2032)
• Figure 4: ARGX-113 Market Size in France, USD million (2019-2032)
• Figure 5: ARGX-113 Market Size in Italy, USD million (2019-2032)
• Figure 6: ARGX-113 Market Size in Spain, USD million (2019-2032)
• Figure 7: ARGX-113 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: ARGX-113 Market Size in Japan, USD million (2019-2032)

“"ARGX-113 Emerging Drug Insight and Market Forecast - 2032" ” report provides comprehensive insights about ARGX-113 for immune thrombocytopenic purpura (ITP) in the seven major markets. A detailed picture of the ARGX-113 for ITP in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ARGX-113 for ITP. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ARGX-113 market forecast analysis for ITP in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ITP.

Drug Summary:

Efgartigimod (ARGX-113) is an investigational therapy for IgG-mediated autoimmune diseases and was designed to exploit the natural interaction between IgG antibodies and the recycling receptor FcRn Argenx, designed efgartigimod to degrade circulating disease-causing autoimmune antibodies and has potential in many large and orphan indications, namely multiple sclerosis, ITP, systemic lupus erythematosus, myasthenia gravis, and skin-blistering diseases.

Efgartigimod is the Fc-portion of an IgG1 antibody modified by the Argenx proprietary ABDEG technology to increase its affinity for FcRn beyond normal IgG antibodies. As a result, efgartigimod blocks antibody recycling through FcRn binding and leads to fast depletion of the autoimmune disease-causing IgG autoantibodies. The development work on efgartigimod is conducted in close collaboration with Prof. E. Sally Ward (University of Texas Southwestern Medical and Texas A&M University Health Science Center, a part of Texas A & M University (TAMHSC)). The drug is currently in Phase III trial for adult patients with primary ITP.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the ARGX-113 description, mechanism of action, dosage and administration, research and development activities in immune thrombocytopenic purpura (ITP).
• Elaborated details on ARGX-113 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ARGX-113 research and development activities in ITP across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ARGX-113.
• The report contains forecasted sales of ARGX-113 for ITP till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ITP.
• The report also features the SWOT analysis with analyst views for ARGX-113 in ITP.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ARGX-113 Analytical Perspective by DelveInsight

In-depth ARGX-113 Market Assessment

This report provides a detailed market assessment of ARGX-113 for immune thrombocytopenic purpura (ITP) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

ARGX-113 Clinical Assessment

The report provides the clinical trials information of ARGX-113 for ITP covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for immune thrombocytopenic purpura (ITP) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ARGX-113 dominance.
• Other emerging products for ITP are expected to give tough market competition to ARGX-113 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ARGX-113 in ITP.
• Our in-depth analysis of the forecasted sales data of ARGX-113 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ARGX-113 in ITP.

Key Questions:

• What is the product type, route of administration and mechanism of action of ARGX-113?
• What is the clinical trial status of the study related to ARGX-113 in immune thrombocytopenic purpura (ITP) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ARGX-113 development?
• What are the key designations that have been granted to ARGX-113 for ITP?
• What is the forecasted market scenario of ARGX-113 for ITP?
• What are the forecasted sales of ARGX-113 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to ARGX-113 for ITP?
• Which are the late-stage emerging therapies under development for the treatment of ITP?

Table of Contents

1. Report Introduction

2. ARGX-113 Overview in ITP

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. ARGX-113 Market Assessment

• 5.1. Market Outlook of ARGX-113 in ITP
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of ARGX-113 in the 7MM for ITP
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of ARGX-113 in the United States for ITP
  • 5.3.2. Market Size of ARGX-113 in Germany for ITP
  • 5.3.3. Market Size of ARGX-113 in France for ITP
  • 5.3.4. Market Size of ARGX-113 in Italy for ITP
  • 5.3.5. Market Size of ARGX-113 in Spain for ITP
  • 5.3.6. Market Size of ARGX-113 in the United Kingdom for ITP
  • 5.3.7. Market Size of ARGX-113 in Japan for ITP

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options